New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

US FDA Decision Expected 1 December

Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.

Roche_Logo_Glass — Roche's Tecentriq is trailing Merck's Keytruda in advanced NSCLC, but could be first approved in an adjuvant setting.

Roche has presented new data to support the use of Tecentriq as an adjuvant treatment in early-stage non-small cell lung cancer (NSCLC), where it could soon be the first immunotherapy to gain approval.

Currently more than half of all people who are treated with surgery for early-stage (Stage II-IIIA) NSCLC see their cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.